{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:25:59Z","timestamp":1787009159052,"version":"build-2736575974"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U22A20279"],"award-info":[{"award-number":["U22A20279"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key project of Chongqing technology development and application program","award":["CSTB2023TIAD-KPX0060"],"award-info":[{"award-number":["CSTB2023TIAD-KPX0060"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Proteinuria and hematuria are both significant predictors of impaired kidney function in IgA nephropathy (IgAN). We evaluated the efficacy and safety of ambrisentan, a selective endothelin A receptor antagonist, as adjunctive therapy in a real-world cohort of high-risk IgAN patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective, single-center study, we analyzed 169 patients with biopsy-proven IgAN who received adjunctive ambrisentan for \u22656 months. A propensity score-matched historical control group (138 pairs) was generated from patients receiving standard care prior to the ambrisentan era. Laboratory test results were gathered at baseline, and at 3 and 6 months. A generalized estimating equation model was employed to adjust for potential confounders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the full ambrisentan cohort (n = 169), median urinary protein-to-creatinine ratio (UPCR) decreased significantly by 58.4% (95% confidence interval [CI], 49.8\u201362.3) at 6 months, with 75.7% of patients achieving a \u226530% reduction. Hematuria was also significantly reduced (P &amp;lt; .001), and kidney function remained stable. Compared to the matched controls, the ambrisentan group (n = 138 after propensity score-matching) demonstrated a greater median relative reduction in UPCR (\u221259.7% vs. \u221253.7%; P = .015). However, a decrease in hemoglobin levels was observed, with an increased incidence of anemia. The proteinuria-lowering effect was enhanced in patients concurrently receiving angiotensin converting enzyme inhibitors (ACEi)\/ angiotensin receptor blockers (ARBs) or finerenone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this analysis incorporating a matched historical control, adjunctive ambrisentan significantly reduced proteinuria and hematuria in patients with IgAN without affecting kidney function. The proteinuria-lowering effect was more pronounced when ambrisentan was added to an ACEi\/ARB or finerenone. Notably, a significant decline in hemoglobin levels was observed, indicating a need for monitoring. These results warrant further prospective trials to confirm the long-term renal benefits and safety of ambrisentan in IgAN.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/joneph\/aajaf052","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T17:14:50Z","timestamp":1772212490000},"page":"335-343","source":"Crossref","is-referenced-by-count":1,"title":["Ambrisentan as adjunctive therapy for IgA nephropathy: a retrospective single-center analysis"],"prefix":"10.1093","volume":"39","author":[{"given":"Jiawen","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Nephrology, The Key Laboratory for the Prevention and Treatment of Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tangli","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Key Laboratory for the Prevention and Treatment of Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Key Laboratory for the Prevention and Treatment of Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Key Laboratory for the Prevention and Treatment of Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangyu","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Key Laboratory for the Prevention and Treatment of Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Key Laboratory for the Prevention and Treatment of Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaobo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Key Laboratory for the Prevention and Treatment of Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiachuan","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Key Laboratory for the Prevention and Treatment of Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9750-3285","authenticated-orcid":false,"given":"Jinghong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Key Laboratory for the Prevention and Treatment of Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"2026061607060046600_aajaf052-B1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41572-023-00476-9","article-title":"Iga nephropathy","volume":"9","author":"Stamellou","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"2026061607060046600_aajaf052-B2","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2026061607060046600_aajaf052-B3","doi-asserted-by":"publisher","first-page":"ii19","DOI":"10.1093\/ckj\/sfad232","article-title":"Microscopic hematuria as a risk factor for IgAN progression: considering this biomarker in selecting and monitoring patients","volume":"16","author":"Zand","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026061607060046600_aajaf052-B4","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1681\/ASN.2011030221","article-title":"Current therapy for IgA nephropathy","volume":"22","author":"Floege","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2026061607060046600_aajaf052-B5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"2026061607060046600_aajaf052-B6","doi-asserted-by":"publisher","first-page":"sfaf125","DOI":"10.1093\/ckj\/sfaf125","article-title":"Efficacy and safety of finerenone in IgA nephropathy: an observational multicentre study","volume":"18","author":"Wang","year":"2025","journal-title":"Clin Kidney J"},{"key":"2026061607060046600_aajaf052-B7","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"2026061607060046600_aajaf052-B8","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in patients with IgA nephropathy","volume":"392","author":"Heerspink","year":"2025","journal-title":"N Engl J Med"},{"key":"2026061607060046600_aajaf052-B9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1681\/ASN.0000000538","article-title":"The selective endothelin receptor antagonist SC0062 in IgA nephropathy: a randomized double-blind placebo-controlled clinical trial","volume":"36","author":"Heerspink","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"2026061607060046600_aajaf052-B10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3969\/j.issn.1671-4091.2024.10.003","article-title":"Efficacy and safety analysis of ambrisentan treatment for IgA nephropathy","volume":"23","author":"Li","year":"2024","journal-title":"Chin J Blood Purif"},{"key":"2026061607060046600_aajaf052-B11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"key":"2026061607060046600_aajaf052-B12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2174\/157489006775244263","article-title":"The vascular endothelin system in hypertension\u2014recent patents and discoveries","volume":"1","author":"Hynynen","year":"2006","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"key":"2026061607060046600_aajaf052-B13","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1161\/HYPERTENSIONAHA.110.167486","article-title":"Selective endothelin-a receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease","volume":"57","author":"Dhaun","year":"2011","journal-title":"Hypertension"},{"key":"2026061607060046600_aajaf052-B14","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1172\/JCI119297","article-title":"Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension","volume":"99","author":"Hocher","year":"1997","journal-title":"J Clin Invest"},{"key":"2026061607060046600_aajaf052-B15","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1161\/HYPERTENSIONAHA.110.156570","article-title":"Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat","volume":"56","author":"Saleh","year":"2010","journal-title":"Hypertension"},{"key":"2026061607060046600_aajaf052-B16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000444719","article-title":"Vascular endothelial growth factor and podocyte protection in chronic hypoxia: effects of endothelin-a receptor antagonism","volume":"43","author":"Harvey","year":"2016","journal-title":"Am J Nephrol"},{"key":"2026061607060046600_aajaf052-B17","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1093\/ndt\/gfae021","article-title":"Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy","volume":"39","author":"Nagasawa","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026061607060046600_aajaf052-B18","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/MNH.0000000000000716","article-title":"Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease","volume":"30","author":"Smeijer","year":"2021","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026061607060046600_aajaf052-B19","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1007\/s11255-025-04548-5","article-title":"Early post-treatment remission of proteinuria is associated with long-term prognosis in patients with immunoglobulin A nephropathy","volume":"57","author":"Fang","year":"2025","journal-title":"Int Urol Nephrol"},{"key":"2026061607060046600_aajaf052-B20","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1053\/j.ajkd.2023.12.016","article-title":"Time-varying proteinuria and progression of IgA nephropathy: a cohort study","volume":"84","author":"Tang","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2026061607060046600_aajaf052-B21","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"2026061607060046600_aajaf052-B22","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1681\/ASN.2010080869","article-title":"Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy","volume":"22","author":"Kohan","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2026061607060046600_aajaf052-B23","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.kint.2020.09.026","article-title":"New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction","volume":"99","author":"Heerspink","year":"2021","journal-title":"Kidney Int"},{"key":"2026061607060046600_aajaf052-B24","doi-asserted-by":"publisher","first-page":"e032971","DOI":"10.1161\/JAHA.123.032971","article-title":"Nonsteroidal mineralocorticoid receptor antagonist finerenone improves diastolic dysfunction in preclinical nondiabetic chronic kidney disease","volume":"13","author":"Lima Posada","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026061607060046600_aajaf052-B25","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1042\/CS20220212","article-title":"The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with type 2 diabetes and chronic kidney disease","volume":"136","author":"Barrera-Chimal","year":"2022","journal-title":"Clin Sci"},{"key":"2026061607060046600_aajaf052-B26","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s40620-025-02240-6","article-title":"Effectiveness and safety of finerenone in non-diabetic patients with IgA nephropathy","volume":"38","author":"Tang","year":"2025","journal-title":"J Nephrol"},{"key":"2026061607060046600_aajaf052-B27","doi-asserted-by":"publisher","first-page":"553","DOI":"10.4239\/wjd.v11.i11.553","article-title":"Endothelin receptor antagonists for the treatment of diabetic nephropathy: a meta-analysis and systematic review","volume":"11","author":"Zhang","year":"2020","journal-title":"World J Diabetes"},{"key":"2026061607060046600_aajaf052-B28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s40264-015-0275-y","article-title":"Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension","volume":"38","author":"Aversa","year":"2015","journal-title":"Drug Saf"},{"key":"2026061607060046600_aajaf052-B29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1159\/000072705","article-title":"Effects of an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitors on burst forming units-erythroid in chronic hemodialysis patients","volume":"23","author":"Naito","year":"2003","journal-title":"Am J Nephrol"},{"key":"2026061607060046600_aajaf052-B30","doi-asserted-by":"publisher","first-page":"e003896","DOI":"10.1161\/JAHA.116.003896","article-title":"Clinical adverse effects of endothelin receptor antagonists: insights from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials","volume":"5","author":"Wei","year":"2016","journal-title":"J Am Heart Assoc"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/2\/335\/67157926\/aajaf052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/2\/335\/67157926\/aajaf052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:11:21Z","timestamp":1781608281000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/39\/2\/335\/8501321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,27]]},"published-print":{"date-parts":[[2026,6,16]]}},"URL":"https:\/\/doi.org\/10.1093\/joneph\/aajaf052","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,27]]}}}